<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01480258</url>
  </required_header>
  <id_info>
    <org_study_id>V419-008</org_study_id>
    <secondary_id>2010-021491-28</secondary_id>
    <nct_id>NCT01480258</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)</brief_title>
  <official_title>A Phase III Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MCM Vaccines B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MCM Vaccines B.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine whether subjects who receive V419 at 2, 4, and 11 to 12 months of
      age have an acceptable response to the vaccine. this study will also determine whether the
      immune response to V419 is similar to that of subjects who received a licensed vaccine
      control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of responders to polyribosylribitol phosphate (PRP) antigen</measure>
    <time_frame>Post-dose 3 (12 to 13 Months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of responders to diphtheria antigen</measure>
    <time_frame>Post-dose 3 (12 to 13 Months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of responders to tetanus antigen</measure>
    <time_frame>Post-dose 3 (12 to 13 Months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of responders to inactivated poliovirus (IPV) antigens</measure>
    <time_frame>Post-dose 3 (12 to 13 Months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of responders to hepatitis B surface (HBsAg) antigen</measure>
    <time_frame>Post-dose 3 (12 to 13 Months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of responders to pertussis antigens</measure>
    <time_frame>Post-dose 3 (12 to 13 Months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of responders to polyribosylribitol phosphate (PRP) antigen</measure>
    <time_frame>Post-dose 2 (5 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer (GMT) for rotavirus antigens</measure>
    <time_frame>Post-dose 2 (5 Months)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1315</enrollment>
  <condition>Bacterial Infections</condition>
  <condition>Virus Diseases</condition>
  <arm_group>
    <arm_group_label>V419</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>V419 + Rotavirus vaccine + Prevenar 13</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infanrix hexa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>INFANRIX hexa + rotavirus vaccine + Prevenar 13</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V419</intervention_name>
    <description>Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Outer Membrane Protein Complex], and Hepatitis B [Recombinant] Vaccine 0.5 mL intramuscular injection at 2, 4, and 11 to 12 months of age</description>
    <arm_group_label>V419</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rotavirus vaccine</intervention_name>
    <description>Rotarix 1.5 mL oral dose at 2 and 4 months of age (subset 1) or RotaTeq 2 mL oral dose at 2, 4 and 5 months of age (subset 2)</description>
    <arm_group_label>V419</arm_group_label>
    <arm_group_label>Infanrix hexa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevenar 13</intervention_name>
    <description>Prevenar 13 0.5 mL intramuscular injection at 2, 4, and 11 to 12 months of age</description>
    <arm_group_label>V419</arm_group_label>
    <arm_group_label>Infanrix hexa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>INFANRIX hexa</intervention_name>
    <description>INFANRIX hexa 0.5 mL intramuscular injection at 2, 4 and 11 to 12 months of age</description>
    <arm_group_label>V419</arm_group_label>
    <arm_group_label>Infanrix hexa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy infant able to attend all study visits

          -  Parent(s)/legal representative are able to read, understand, and complete study
             questionnaires

        Exclusion Criteria:

          -  History of congenital or acquired immunodeficiency

          -  Received or is expected to receive immunosuppressive agents or systemic
             immunomodulatory steroids

          -  History of leukemia, lymphoma, malignant melanoma, or myeloproliferative disorder

          -  Hypersensitivity to any of the vaccine components or history of a life-threatening
             reaction to a vaccine containing the same substances as the study vaccines or
             concomitant study vaccines

          -  Has any chronic illness that could interfere with study conduct or completion

          -  Received any immune globulin, blood, or blood-derived products since birth

          -  Received a dose of hepatitis B vaccine prior to study entry

          -  Vaccinated with any acellular pertussis or whole cell pertussis based combination
             vaccines, Haemophilus influenzae type b conjugate, poliovirus, pneumococcal conjugate
             or pneumococcal

          -  polysaccharide, rotavirus vaccine, or combination thereof

          -  Fever within 24 hours prior to enrollment

          -  Received any non-study vaccine within 30 days prior to enrollment, except for
             inactivated influenza vaccine, which is permitted 14 days or more prior to enrolment

          -  Has a coagulation disorder

          -  Has developmental delay or neurological disorder

          -  Participant or his/her mother has a medical history of hepatitis B surface antigens
             (HBsAg) seropositivity

          -  History of Haemophilus influenzae type b, hepatitis B, diphtheria, tetanus, pertussis,
             poliomyelitis, rotavirus gastroenteritis, or invasive pneumococcal infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>46 Days</minimum_age>
    <maximum_age>89 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0080019</name>
      <address>
        <city>Espoo</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0080005</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational site 0080018</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0080003</name>
      <address>
        <city>Jarvenpaa</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0080021</name>
      <address>
        <city>Kokkola</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0080020</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0080016</name>
      <address>
        <city>Pori</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0080006</name>
      <address>
        <city>Seinajoki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0080001</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0080002</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0080017</name>
      <address>
        <city>Vantaa</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0080024</name>
      <address>
        <city>Chiavari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0080014</name>
      <address>
        <city>Este</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0080011</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0080013</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0080022</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0080025</name>
      <address>
        <city>Ragusa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0080023</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0080012</name>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0080009</name>
      <address>
        <city>Linkoeping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0080008</name>
      <address>
        <city>Malmo</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0080007</name>
      <address>
        <city>Orebro</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPMSD Investigational Site 0080010</name>
      <address>
        <city>Umea</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Italy</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2011</study_first_submitted>
  <study_first_submitted_qc>November 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2011</study_first_posted>
  <last_update_submitted>February 27, 2017</last_update_submitted>
  <last_update_submitted_qc>February 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>combination vaccine</keyword>
  <keyword>diphtheria</keyword>
  <keyword>pertussis</keyword>
  <keyword>tetanus</keyword>
  <keyword>hepatitis B</keyword>
  <keyword>Hep B</keyword>
  <keyword>Haemophilus influenzae b</keyword>
  <keyword>Hib</keyword>
  <keyword>polio</keyword>
  <keyword>poliovirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

